Categories
Connect with us on LinkedIn
Beyond the EHR: meeting the FDA’s new real-world evidence standards
The FDA’s December 2025 device guidance and March 2026 ICH M14 adoption raise the bar for RWE programs....
Biotech AI strategy for clinical teams | LinkedIn Live
LinkedIn Live event tile featuring Derk Arts, CEO of Castor, and Solomon Babani, Founder and CEO of Symbiosis...
The ePRO blueprint for pain trials: Optimizing data capture from protocol design to efficacy endpoints
The 11-point electronic Numeric Rating Scale (eNRS) is now the preferred digital standard for BYOD pain trials, recommended...
Early-stage biotech’s AI advantage is a window that closes. Sol Babani and Derk Arts on how to use it.
Sol Babani and Derk Arts on why early-stage biotech must build AI-native operations, not retrofit old ones. Decision...
Better Evidence Starts with Better Infrastructure
Meet Castor at ISPOR US 2026 | May 17-20 | Philadelphia, PA
Schedule a meeting with the Castor team at ISPOR US 2026. See Castor Catalyst AI for real-world evidence...
Joel White’s Q4 CRO breakdown: strong bookings, a sell-off that didn’t match, and the disruption gap nobody is talking about
Q4 CRO revenues grew. Bookings accelerated. So why the AI panic? Joel White breaks down what the numbers...
What AI replaces in Phase 2/3 data management, and the edit check question your team hasn’t asked yet
Alison Bishop and Derk Arts on what AI actually replaces in Phase 2/3 data management, with a deep...
Castor adds nearly 10 commercial Phase II/III eCOA studies in H2 2025
Nearly 10 Phase II/III eCOA studies and 12 validated instruments across four therapeutic areas. Castor’s H2 2025 platform...
Data management without the coordination friction
Castor replaces disconnected DM tools and CRO handoffs with one platform and one expert team. Fixed-fee, submission-ready.
Biotech clinical trial data management
Castor delivers expert data management for biotech trials. Submission-ready from day one. No intermediary layers.
ICH E6(R3) compliance for biotech studies
See how Castor's unified platform helps biotech sponsors meet ICH E6(R3) oversight, data integrity, and site burden requirements.
ePRO for biotech: capture economic evidence from day one
Castor ePRO helps biotech sponsors capture HEOR-ready evidence from Phase I/II. Audit-proof, 92%+ participant compliance.
Phase 4 and real-world evidence: not a spectrum, a strategic choice
Phase 4 is a post-approval interventional trial that fulfills regulatory commitments. Real-world evidence spans PASS, PAES, HEOR, natural...
Castor Joins C-Path eCOA Consortium, Surpassing 300 Industry Study Milestone
Castor joins the Critical Path Institute (C-Path) eCOA Consortium, bringing insights from 300+ industry studies to advance participant-centric...
Obesity RWD Compliance: The Direct-to-Patient Guide
Over 2,000 active obesity and GLP-1 studies are competing for the same patients. Most still run on traditional...
Own Your Data, Accelerate Your Cure Castor Catalyst — Rare Disease Insight Brief
Rare disease foundations no longer need to wait for pharmaceutical industry interest to develop treatments for their communities....
ICH E6(R3) is here: what your centralized monitoring strategy needs right now
ICH E6(R3) is in effect. Castor's recap covers centralized monitoring, sponsor accountability, and closing the biotech RBQM gap.
Practical ICH E6(R3) Oversight for Your Centralized Monitoring Strategy – On Demand
Adopting ICH E6(R3) requires a shift from site-based monitoring to centralized oversight. Watch this on-demand Product Spotlight to...
Connect with us on LinkedIn
